Anxious depression and early changes in the HAMD-17 anxiety-somatization factor items and antidepressant treatment outcome.
The objective of this study was to assess the relationship between early changes in anxiety/somatization symptoms and treatment outcome among major depressive disorder patients during a 12-week trial of fluoxetine. We also examined the relationship between anxious depression and treatment response. Five hundred and ten major depressive disorder patients received 12 weeks of fluoxetine with flexible dosing [target dosages: 10 mg/day (week 1), 20 mg/day (weeks 2-4), 40 mg/day (weeks 4-8), and 60 mg/day (weeks 5-12)]. We assessed the relationship between early changes in 17-item Hamilton Rating Scale for Depression (HAMD-17)-anxiety/somatization factor items and depressive remission, as well as whether anxious depression at baseline predicted remission at study endpoint. Baseline HAMD-17 scores were considered as covariates and the Bonferroni correction (P < or = 0.008) was used for multiple comparisons. Adjusting for baseline HAMD-17 scores, patients who experienced greater early improvement in somatic symptoms (gastrointestinal) were significantly more likely to attain remission (HAMD-17 <8) at endpoint than those without early improvement (P=0.006). Early changes in the remaining items did not predict remission, nor did anxious depression at baseline. In conclusion, among the anxiety/somatization factor items, only early changes in somatic symptoms (gastrointestinal) predicted remission. Future studies are warranted to further investigate this relationship as well as that between anxious depression and treatment outcome.
Farabaugh
Amy H
AH
Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA.
Bitran
Stella
S
Witte
Janet
J
Alpert
Jonathan
J
Chuzi
Sarah
S
Clain
Alisabet J
AJ
Baer
Lee
L
Fava
Maurizio
M
McGrath
Patrick J
PJ
Dording
Christina
C
Mischoulon
David
D
Papakostas
George I
GI
D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000627:therapeutic use*; D001007:Anxiety / Q000188:drug therapy*; D003865:Major Depressive Disorder / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy*; D005260:Female; D005473:Fluoxetine / Q000008:administration & dosage / Q000627:therapeutic use*; D005767:Gastrointestinal Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D012074:Remission Induction; D016896:Treatment Outcome
D018687:Antidepressive Agents, Second-Generation; D005473:Fluoxetine
Acta Psychiatr Scand. 2009 Apr;119(4):298-303
19032701
Biol Psychiatry. 2007 Sep 1;62(5):407-14
17217921
J Psychosom Res. 2008 Jun;64(6):605-12
18501261
Prim Care Companion J Clin Psychiatry. 2004;6(Suppl 1):12-6
16001092
Clinics (Sao Paulo). 2009;64(7):629-35
19606237
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62
14399272
Psychopharmacol Bull. 1988;24(1):183-8
3290940
J Clin Psychiatry. 2005 Aug;66(8):1064-70
16086624
Biol Psychiatry. 1997 Oct 1;42(7):568-76
9376453
Int Clin Psychopharmacol. 2005 Mar;20(2):87-91
15729083
J Clin Psychiatry. 2007 Jan;68(1):52-7
17284130
Am J Psychiatry. 2008 Mar;165(3):342-51
18172020
Psychol Med. 2003 Jul;33(5):839-45
12877398
Am J Psychiatry. 2006 Sep;163(9):1542-8
16946178